Table 2.

Adjusted incidence rate ratio for healthcare utilization in cohort of psoriasis patients with comorbidities

Comorbidity	Outpatient visits IRR Estimate	Lower CL	Upper CL	p value	Hospitalisation visits IRR Estimate	Lower CL	Upper CL	p value	Emergency Room Visits IRR Estimate	Lower CL	Upper CL	P value
Psoriatic arthritis	1.30	1.27	1.32	<0.0001	1.40	1.27	1.55	<0.0001	1.36	1.26	1.46	<0.0001
Cardiovascular disease	1.51	1.48	1.53	<0.0001	2.60	2.41	2.79	<0.0001	2.34	2.22	2.48	<0.0001
Depression	1.34	1.31	1.37	<0.0001	2.05	1.85	2.26	<0.0001	1.99	1.85	2.14	<0.0001
Anxiety	1.36	1.33	1.39	<0.0001	1.82	1.61	2.05	<0.0001	2.15	1.98	2.34	<0.0001
Diabetes	1.37	1.35	1.39	<0.0001	1.93	1.79	2.08	<0.0001	1.77	1.67	1.88	<0.0001
Hyperlipidemia	1.21	1.20	1.23	<0.0001	1.09	1.02	1.16	0.0122	1.16	1.10	1.22	<0.0001
Hypertension	1.31	1.29	1.33	<0.0001	1.71	1.60	1.83	<0.0001	1.63	1.56	1.72	<0.0001
Obesity	1.38	1.35	1.42	<0.0001	2.17	1.93	2.45	<0.0001	1.89	1.73	2.08	<0.0001
Cerebrovascular disease	1.41	1.37	1.46	<0.0001	2.08	1.84	2.35	<0.0001	2.01	1.81	2.23	<0.0001
Peripheral vascular disease	1.47	1.43	1.52	<0.0001	2.38	2.10	2.69	<0.0001	1.95	1.75	2.16	<0.0001
Any of the above comorbiditiesa	1.49	1.47	1.51	<0.0001	2.03	1.87	2.19	<0.0001	1.84	1.75	1.94	<0.0001

Note: For each comorbidity, the reference group is the patients who do not have the respective comorbidity

IRR incidence rate ratio, CL confidence limit

^aAny of the above comorbidities means if patients have any of the either comorbidities mentioned above

Data for outpatient visits, hospitalization visits and emergency room visits for each of the comorbidities for the controlled variables are not reported here, but these can be made available upon request